Summit Global Investments purchased a new position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 3,453 shares of the company's stock, valued at approximately $541,000.
A number of other hedge funds and other institutional investors have also recently modified their holdings of KRYS. Entropy Technologies LP bought a new stake in Krystal Biotech in the 4th quarter worth approximately $548,000. Summit Trail Advisors LLC purchased a new stake in Krystal Biotech during the third quarter valued at approximately $1,893,000. Swiss National Bank raised its position in Krystal Biotech by 8.0% in the third quarter. Swiss National Bank now owns 39,100 shares of the company's stock worth $7,117,000 after acquiring an additional 2,900 shares during the period. Janney Montgomery Scott LLC boosted its stake in shares of Krystal Biotech by 42.0% during the 4th quarter. Janney Montgomery Scott LLC now owns 52,592 shares of the company's stock worth $8,239,000 after acquiring an additional 15,545 shares during the last quarter. Finally, Citigroup Inc. grew its holdings in Krystal Biotech by 65.4% during the third quarter. Citigroup Inc. now owns 35,084 shares of the company's stock valued at $6,386,000 after purchasing an additional 13,874 shares during the period. 86.29% of the stock is owned by institutional investors.
Krystal Biotech Price Performance
Shares of KRYS traded up $1.17 during mid-day trading on Friday, reaching $183.92. 224,610 shares of the company's stock traded hands, compared to its average volume of 289,479. Krystal Biotech, Inc. has a 12 month low of $141.72 and a 12 month high of $219.34. The stock has a market cap of $5.30 billion, a P/E ratio of 61.51 and a beta of 0.87. The stock's 50-day moving average is $170.11 and its two-hundred day moving average is $173.84.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping analysts' consensus estimates of $1.29 by $0.23. The business had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business's revenue was up 116.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.30 earnings per share. Research analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.
Analyst Ratings Changes
A number of equities research analysts have issued reports on KRYS shares. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $215.00 price objective on shares of Krystal Biotech in a report on Thursday, February 20th. HC Wainwright reiterated a "buy" rating and issued a $221.00 price target on shares of Krystal Biotech in a report on Friday, February 28th. Jefferies Financial Group began coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They set a "buy" rating and a $245.00 price objective for the company. Citigroup lifted their target price on Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a report on Thursday, February 20th. Finally, Chardan Capital raised their price target on Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a report on Thursday, February 20th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Krystal Biotech currently has a consensus rating of "Buy" and an average target price of $220.00.
Get Our Latest Stock Analysis on KRYS
Insider Activity at Krystal Biotech
In other news, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the sale, the chief accounting officer now owns 12,604 shares of the company's stock, valued at approximately $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the transaction, the insider now directly owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. This trade represents a 1.68 % decrease in their position. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by company insiders.
About Krystal Biotech
(
Free Report)
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Read More
Before you consider Krystal Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.
While Krystal Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
